PNC Financial Services Group
TTNP

PNC Financial Services Group’s Titan Pharmaceuticals TTNP Stock Holding History

PNC Financial Services Group’s Portfolio TTNP Stock Details TTNP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-10
Closed -$156 – 4820
2022
Q4 		$156 Buy
+10
New +$189 ﹤0.01% 4660
2018
Q3 		– Sell
-1
Closed -$3K – 4243
2018
Q2 		$3K Buy
+1
New +$3.35K ﹤0.01% 3948

Other funds holding TTNP

Truist Financial
Truist Financial Charlotte, North Carolina $74.2B AUM 21.09% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
LFA
Level Financial Advisors East Amherst, New York $448M AUM 16.6% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

PNC Financial Services Group's TTNP Position: Q1 2023 in Review

PNC Financial Services Group sold out of Titan Pharmaceuticals (TTNP) in Q1 2023, closing a stake of 10 shares — an estimated $156 sold.

PNC Financial Services Group first reported a position in TTNP in Q2 2018 and held it in 2 quarters. The position peaked at $3K in Q2 2018. 17 funds tracked by Wall St. Rank hold TTNP as of Q1 2023.

  • PNC Financial Services Group reported no remaining Titan Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
  • PNC Financial Services Group sold 10 Titan Pharmaceuticals shares in Q1 2023, an estimated $156.
  • PNC Financial Services Group first reported a position in Titan Pharmaceuticals in Q2 2018 and held it in 2 quarters.
  • PNC Financial Services Group's Titan Pharmaceuticals position peaked at $3K in Q2 2018.
  • 17 funds tracked by Wall St. Rank held Titan Pharmaceuticals as of Q1 2023.

Based on PNC Financial Services Group's 13F filing for Q1 2023, filed 15 May 2023.